You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

~ Buy the VELTASSA (patiromer sorbitex calcium) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VELTASSA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Veltassa

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00868439 ↗ Evaluation of Patiromer in Heart Failure Patients Completed Medpace, Inc. Phase 2 2009-04-01 The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
NCT00868439 ↗ Evaluation of Patiromer in Heart Failure Patients Completed Relypsa, Inc. Phase 2 2009-04-01 The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
NCT01130597 ↗ Evaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney Disease Completed Relypsa, Inc. Phase 2 2010-05-01 The purpose of this study was to evaluate the feasibility of individualized titration of patiromer according to serum potassium. This study also assessed the safety and tolerability of patiromer and the effects of patiromer on serum potassium in heart failure (HF) participants with chronic kidney disease (CKD).
NCT01371747 ↗ Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) Completed Relypsa, Inc. Phase 2 2011-06-01 This study determined the optimal starting dose of patiromer in treating hyperkalemia in participants with hypertension and diabetic nephropathy who were already receiving ACEI and/or ARB drugs, with or without spironolactone. This study also evaluated the efficacy and safety of patiromer and the long term use of patiromer.
NCT01810939 ↗ A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Completed Relypsa, Inc. Phase 3 2013-02-01 The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium). The study also evaluated the effect of withdrawing patiromer treatment and assessed whether chronic treatment with patiromer prevented the recurrence of hyperkalemia. The safety of patiromer treatment was also evaluated.
NCT02033317 ↗ An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis Terminated Relypsa, Inc. Phase 2 2008-08-01 This study assessed the pharmacodynamic effects of patiromer on serum potassium in participants on hemodialysis.
NCT02694744 ↗ Patiromer With or Without Food for the Treatment of Hyperkalemia Completed Relypsa, Inc. Phase 4 2016-02-01 The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high potassium in the blood).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Veltassa

Condition Name

Condition Name for Veltassa
Intervention Trials
Hyperkalemia 9
Heart Failure 2
Chronic Kidney Diseases 1
Heart Failureļ¼ŒCongestive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Veltassa
Intervention Trials
Hyperkalemia 11
Kidney Diseases 6
Renal Insufficiency, Chronic 6
Heart Failure 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Veltassa

Trials by Country

Trials by Country for Veltassa
Location Trials
United States 83
Brazil 12
Spain 9
Germany 7
Mexico 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Veltassa
Location Trials
California 6
Texas 6
New York 6
Florida 6
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Veltassa

Clinical Trial Phase

Clinical Trial Phase for Veltassa
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 2 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Veltassa
Clinical Trial Phase Trials
Completed 7
Active, not recruiting 2
Terminated 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Veltassa

Sponsor Name

Sponsor Name for Veltassa
Sponsor Trials
Relypsa, Inc. 10
Vifor Pharma, Inc. 2
University of Glasgow 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Veltassa
Sponsor Trials
Industry 14
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.